- MDL 28170
- CA 074
- CA-074 Me
- E-64-c
- E 64d
- Odanacatib (MK-0822)
| Cathepsin S inhibitorBlocks MHCII antigen presentation |
Sample solution is provided at 25 µL, 10mM.
Quality Control & MSDS
- View current batch:
- Purity = 98.96%
- COA (Certificate Of Analysis)
- HPLC(Retest)
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
| A slow, tight-binding reversible inhibitor of recombinant cathepsin S (Ki = 185 pM). Exhibits about 410-fold greater selectivity for cathepsin S compared to cathepsin B (Ki = 76 nM). | ||||||
| Targets | cathepsin S | |||||
| Ki | 185pM | |||||
| Kinase experiment [1]: | |
Kinase assays | Assays were performed for Cat S, mCat S, Cat B and Cat L by adding enzyme to a concentration of FRET substrate equal to the Km in a 50 mM sodium phosphate buffer (pH 6.5) containing 2.5 mM DTT, 2.5 mM EDTA plus 0.01% Triton X-100. The Cat V and Cat K assays were performed as above, but in a 0.1 M sodium acetate (pH 5.5) buffer containing 2.5 mM DTT, 2.5 mM EDTA plus 0.01% Triton X-100. Km values for the FRET substrate were 25 μM, 25 μM, 20 μM, 37.5 μM, 35 μM, 35 μM and 25 μM for human Cat S, mouse Cat S, human Cat L, human Cat B, human Cat K, human Cat V and human Cat F respectively. |
| Animal experiment [1]: | |
Animal models | Mouse model of abdominal aortic aneurysm (AAA) |
Dosage form | 1, 3, 10, and 30 mg/kg, oral, BID dosing |
Application | The efficacies of Cathepsin S inhibitor was studied in a mouse model of abdominal aortic aneurysm (AAA). Cathepsin S inhibitor exhibited a dose-responsive aortic diameter reduction at 1, 3, 10, and 30 mg/kg. At the lowest dose of 1 mg/kg of Cathepsin S inhibitor, the aortic diameter is reduced by 58%, then 83% at 3 mg/kg, and 87% at 10 mg/kg. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1] Jadhav PK, et al. Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm. ACS Med Chem Lett. 2014 Aug 27;5(10):1138-42. | |
Cathepsin S inhibitor Dilution Calculator
calculate
Cathepsin S inhibitor Molarity Calculator
calculate
| Cas No. | 1373215-15-6 | SDF | Download SDF |
| Synonyms | N/A | ||
| Chemical Name | [(3R,4S)-4-[(4-fluorobenzoyl)amino]-6-[4-(oxetan-3-yl)piperazin-1-yl]-3,4-dihydro-2H-chromen-3-yl] N-methylcarbamate | ||
| Canonical SMILES | CNC(=O)OC1COC2=C(C1NC(=O)C3=CC=C(C=C3)F)C=C(C=C2)N4CCN(CC4)C5COC5 | ||
| Formula | C25H29FN4O5 | M.Wt | 484.52 |
| Solubility | ≥24.25 mg/mL in DMSO, <2.47 mg/ml="" in="" etoh,=""><2.13 mg/ml="" in="" h2o=""> | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
Ki: 0.185 nM
Cathepsin S is a lysosomal cysteine protease, playing an important role in antigen presentation. The inhibition of Cathepsin S is expected to result in immunosuppression, which makes this enzyme an attractive target to potentially treat autoimmune and inflammatory diseases. Cathepsin S inhibitor is a novel Cathepsin S inhibitor.
In vitro: Cathepsin S inhibitor was a slow, tight-binding reversible inhibitor of recombinant cathepsin S, exhibiting greater selectivity for cathepsin S compared to cathepsin B [1].
In vivo: No animal in vivo data available currently
Clinical trial: Oral Cathepsin S inhibitor that blocked MHCII antigen presentation could result in a T-cell-selective immunosuppressant agent with improved safety over the current standard of care for the treatment of rheumatoid arthritis, psoriasis, multiple sclerosis and other autoimmune-based inflammatory diseases [2].
References:[1] Wiener JJ, Sun S, Thurmond RL. Recent advances in the design of cathepsin S inhibitors. Curr Top Med Chem. 2010;10(7):717-32.[2] Lee-Dutra A, Wiener DK, Sun S. Cathepsin S inhibitors: 2004-2010. Expert Opin Ther Pat. 2011;21(3):311-37.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
我用conA和LPS分别刺激脾细胞，当然细胞均有明显的增殖，可是如果把这两种有丝分裂原同时用来刺激细胞时，细胞的增殖明显受到了抑制，比起单独采用ConA或者LPS都低很多。conA和LPS分别刺激T细胞和B细胞的增殖，两者同时加入时，作用应该更强，为什么反而大幅减弱呢？
此外，我研究的这种成分单独刺激皮细胞时，细胞也有一定程度的增殖，但是如果这种物质与conA联合使用时，比起单独用conA时，细胞的增殖程度明显降低了一些，这又是什么原因呢？难道可以解释为我研究的这种物质有类似于LPS的作用——刺激B细胞增殖？
如果真的是这样来解释，哪位大侠能把第一个现象（conA和LPS共同作用产生拮抗）的机理帮我解释一下呢？
当抗体结合到示踪剂上时，340nm的激发光激发铕标分子，导致能量转移到Alexa Fluor 647染料上，结果产生665nm的发射光。荧光的强度与样品中的cAMP含量成反比。
本试剂盒用于检测在GPCR激动剂刺激下活细胞或者细胞膜制备品产生的cAMP。对于偶联Gαs的受体，激动剂刺激导致665nm的荧光强度降低，而拮抗剂则可以逆转这一效应；对于偶联Gαi的受体，在激动剂刺激的同时用forskolin刺激cAMP产生，那么激动剂则抑制forskolin诱导的cAMP的生成，因此对照只给forskolin的细胞组可以通过665nm荧光强度的增加反应激动剂的效应。
该试剂盒的灵敏度很高，室温下反应在20h内是稳定的。本试剂盒适用于在384孔板中进行24μl的微量分析。
2.保存条件
避光2~4℃保存，过期时间见装。
3.盒内试剂
cAMP标准品：1管，1ml。（50μM）
生物素标记的cAMP（b-cAMP）：1管，25μl。
铕标的抗生物素蛋白链菌素：1管，25μl。
荧光标记的cAMP抗体：1管，40μl。
检测缓冲液：1瓶，25ml。
4.需要自配的其他溶液
l Hank’s balanced salt solution (HBSS): NaCl 8.0g、CaCl2 0.14g、KCl 0.4g、 KH2PO4 0.06g、Na2HPO4?7H2O0.09g、MgCl2.6H2O0.10 g、MgSO4.7H2O0.10 g、NaHCO30.35g、葡萄糖1.0g，加H2O至 1000ml (用7.5%NaHCO调节PH值=7.4)
l Versene消化液（1L）：EDTA 0.372 g，NaCl 8.0g，KCl 0.20 g，KH2PO40.20g，Na2HPO4 1.15 g，D-glucouse 0.2 g，pH 7.4
l HEPES缓冲液(1mol/L)：取2.383gHEPES溶于10ml去离子水中。
l 7.5%BSA溶液：取0.75gBSA溶于10ml去离子水中
l 0.5M IBMX溶液：11.11mg IBMX溶于100μl DMSO中，-20℃冻存。
l 刺激缓冲液（SB）：14 ml HBSS(1×)+75μlHEPES(1mol/L)+200μlBSA (7.5%)。(注：在测定细胞cAMP时，反应缓冲液中要加入IBMX 0.5mmol/L)
l 吗啡贮存液(10mM)：盐酸吗啡37.585mg溶于10ml生理盐水中，0.22μm滤膜过滤除菌，4℃保存备用。
l 纳络酮母液(100mM)：纳络酮4mg溶于100μl 生理盐水中，用时工作液按照1:500稀释，溶剂为含有IBMX的反应缓冲液。
抑制剂刺激细胞后，需要用PBS清洗后再做后续实验吗
我做的是细胞因子的刺激和抑制某条通路后观察是否有影响，分组为空白组，空白+抑制剂，刺激组，刺激+抑制剂，最开始用的单因素方差分析，LSD-T和SNK-Q检验，但是同学说我这里面有两个处理因素，所以不能单因素方差分析，应该直接空白和空白+抑制，空白和刺激，刺激和刺激+抑制剂进行独立样本T检验，现在脑子是混乱的，拜托园子里的大神们帮我看看，感激不尽！！
